| abstract |
The invention relates to a compound having general formula (I), wherein: m represents an integer equal to 1 or 2; R1 represents an aryl- or heteroaryl-type group that is optionally substituted by one or more R3 or R4 groups; R2 represents a group having general formula CHR5CONHR6; R3 represents a halogen atom or a hydroxy, cyano, nitro, C1-6-alkyl, C1-6-alkoxy, C1-6-thioalkyl, C1-6-fluoroalkyl, C1-6-fluoroalkoxy, -O-(C2-3-alkylene)-, -O-(C1-3-alkylene)-O-, C1-6-fluorothioalkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkylene, piperidinyl, benzyloxy, piperazinyl, pyrrolidinyl, morpholinyl, phenyloxy, NR7R8, NHCOR7, NHSO2R7, COR7, C02R7, CONR7R8, SO2R7 or SO2NR7R8 group; R4 represents an aryl- or heteroaryl-type group, whereby the R4 group(s) can be substituted by one or more identical or different R3 groups; R5 represents a hydrogen atom or a C1-3-alkyl group; R6 represents a hydrogen atom or a C1-6-alkyl, C3-7-cycloalkyl or C3-7-cycloalkyl-C1-3-alkylene group; and R7 and R8 represent, independently of each other, a hydrogen atom, a C1-3-alkyl group or a phenyl group, said compound taking the form of a base, an acid addition salt, a hydrate or a solvate. The compounds are inhibitors of the FAAH enzyme, which can be used for the treatment of pain, eating disorders, neurological and psychiatric pathologies, etc. |